A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

A detailed and reproducible swine uterus model is described, from surgical procurement to the initiation of machine perfusion, allowing for the study of uterus preservation in transplantation.

Abstract

To date, uterus transplantation is the only option for women with absolute uterine infertility, such as those with Rokitansky syndrome, to experience pregnancy and give birth. Despite the growing interest in uterus transplantation in recent years, several issues still require further research, including ischemia-reperfusion injury and its impact on graft quality and rejection. Recent literature has highlighted a thrombotic complication rate of up to 20% following uterus transplantation. This type of complication may result from hypoxia-induced endothelial cell damage, often leading to uterine graft rejection. Hypoxia is induced during static cold storage, which remains the gold standard for graft preservation in solid organ transplantation. Recently, dynamic preservation using machine perfusion has been shown to improve the long-term storage of conventional and marginal organs by reducing ischemic and hypoxic injury. In this protocol, we aim to describe every surgical step involved in porcine uterus procurement and dynamic preservation, based on both uterine pedicles, to enable the connection and initiation of the machine perfusion protocol.

Introduction

Uterus transplantation (UTx) has significantly developed over the last ten years, with several teams starting clinical research programs. To date, the main indication of UTx is absolute uterine infertility due to uterine agenesis, including the Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. MRKH syndrome is a congenital disorder with a prevalence of one in 5,000 female live births1. UTx could potentially address additional causes of infertility, including those resulting from hysterectomy due to malignant disease, postpartum hemorrhage, uterine fibroids, infectious sequelae, and various congenital malformations. This suggests that approximately 1 in 500 women may be eligible for UTx.

The first-ever clinical UTx occurred in 2000 in Saudi Arabia2, but vascular complications led to a hysterectomy three months later. Since then, several cases of UTx have been performed, based on both living and deceased donors, resulting in more than 80 live births3,4. Similar to the realm of solid organ transplantation and vascularized composite allotransplants (VCA), immune rejection is a significant challenge in UTx.5 Several factors can lead to graft rejection, including microcirculatory failure and venous stasis, both of which can lead to thrombotic complication. In a recent review studying uterine vascularization in transplantation, Kristek et al. reported up to 15% arterial thrombosis and 5% venous thrombosis6. Additionally, cold and warm ischemia are critical factors that must be addressed for successful transplantation, as ischemia-reperfusion injury (IRI) can lead to graft dysfunction and acute rejection7,8. Myocytes respond to ischemic stress by producing lactate for up to 6 h9, after which muscle cell damage is irreversible. The impact of cold ischemia on the myometrium has been documented in clinical studies, and the use of intracellular-like University of Wisconsin solution during static cold storage (SCS) has been shown to improve preservation with better contractile response to prostaglandin and higher ATP concentrations when compared to Ringer's acetate solution10. However, the impact of warm and cold ischemia remains poorly explored in UTx.

SCS remains the gold standard for VCA preservation, including the uterus, and for most solid organ transplants. However, in recent years, significant advancements in machine perfusion systems and preservation solutions have led to a paradigm shift. There is now strong evidence supporting that dynamic machine perfusion can improve and prolong the preservation of healthy and marginal solid organs11,12,13,14,15. This technique is now commonly used in clinical practice for lung, heart, liver, and kidney transplantation14,16,17,18. Dynamic organ preservation demonstrated multiple benefits, including minimizing cold ischemia and hypoxia injuries by providing continuous oxygen and nutrient supply, clearing toxic metabolites, and improving graft quality and viability parameters12,19. Multiple modalities have been developed, ranging from hypothermic to normothermic machine perfusion (with or without oxygen carriers), with several perfusates available, but only a few have been tested on the uterus20. To ensure the substantial contribution of such research perspectives, relevant preclinical surgical models are of crucial importance.

In this work, subnormothermic machine perfusion (SNMP) is used as an oxygenated dynamic organ preservation method at room temperature (around 20 °C) by circulating a perfusate through a roller pump and an oxygenator. A porcine model is employed that is relevant for studies on UTx and preservation due to its similarities with the human reproductive system in terms of anatomy, physiology, and vessel size21,22. The uterus is procured following circulatory death, providing relevance for donation after cardiac death and suggesting the possibility for a procurement delay after all other relevant solid organs23,24. In addition, this model facilitates the development of uterus preservation studies within established transplant laboratories focusing on other organs, applying the "3Rs" principles25. The aim is to establish a new preservation model based on uterine pedicles and assess its reliability for dynamic preservation. All the procedure steps are detailed, from the hysterectomy to the preservation, encompassing highlighted key points on using SNMP.

The protocol described below preceded a preliminary experiment based on a single pump and a "Y-tubing" inflow system for both uterine arteries (Supplementary Figure 1). After 4 h-SNMP, the organ gained over 50% of its initial weight. Flow, pressure, resistance, and weight variation are shown in Supplementary Figure 2. A single perfusion system separated into two inflows did not allow modulation of each flow rate to each side's pressure. In this case, SNMP led to substantial edema in half of the organ (Supplementary Figure 3). This system proved unsuitable for the uterine model, partly because it should not be considered a perfectly symmetrical model. Therefore, two systems of machine perfusion were used in this protocol, one for each uterine artery.

Protocol

All animals received humane care following the National Institute of Health Guide for the Care and Use of Laboratory Animals, and the protocols were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (IACUC). Overall, 6 female Yucatan minipigs weighing 30-40 kg were used for uterus procurement, with four uteri undergoing SNMP. All animals were heparinized with one full dose (100 IU/kg) before euthanasia. Organ procurement occurred post-mortem with less than 60 min of warm ischemia. Other organs could have been harvested from the same donor for different studies, according to the "3Rs" principles25. See the Table of Materials for details about all reagents and equipment used in the protocol.

1. Preoperative preparation (day before the surgery)

  1. Prepare the perfusate solution. For subnormothermic machine perfusion, a Steen+ solution optimized for VCA was used26,27. One liter of solution per uterus was used, and the composition is detailed in Table 1.
    NOTE: A large quantity of sodium hydroxide is added to the perfusate with the aim of achieving a pH of around 7.5-7.6. This value is expressly high but necessary as the pH will tend to fall as the machine is circulated and oxygenated with a carbogen mixture (95% oxygen; 5% carbon dioxide).
  2. Set up the machine perfusion system (Figure 1). Check for leaks and bubbles when perfusate is circulated.

2. Post-mortem uterus procurement

NOTE: To simulate donation after cardiac death and/or post-mortem procurement, the animal should be euthanized according to the local IACUC guidelines. Exsanguination should be preferred to intravenous Pentobarbital injection in order to avoid toxicity that could interfere with the study.

  1. Place the euthanized animal in the supine position. Scrub the abdominal area and place sterile drapes.
  2. Make a 10 cm median infra umbilical incision with a #20 blade.
  3. Open the subcutaneous tissue and aponeurosis with a monopolar electric scalpel.
    NOTE: Attention must be paid to not damage intestines by opening the abdominal cavity.
  4. Set aside the small intestine with a surgical gauze and expose the uterus.
    NOTE: The uterine anatomy of the model used is shown in Figure 2A.
  5. Proceed similarly for the left and right sides as follows:
    1. Identify the uterine vessels.
      NOTE: The uterine vein is positioned laterally to the uterine artery (Figure 3).
    2. Create an opening into the broad ligament laterally to the uterine vein with right-angle forceps.
    3. Through this opening, insert 2-0 silk tie sutures to ligate the ovarian vessels and release the uterus from the surrounding connective tissue in the broad ligament using cautery.
    4. Ligate the utero-ovarian vessels with 2-0 silk tie sutures and remove the ovary and tube.
    5. Skeletonize uterine vessels and divide them as close to the internal iliac vessels as possible.
      NOTE: Attention must be paid to keeping the pedicle as long as possible to facilitate cannulation and anticipate pedicle retraction after it has been severed.
    6. Repeat steps 2.5.1-2.5.5 on the opposite side.
  6. Remove the uterus by cutting through the cervix with a monopolar electric scalpel.
    NOTE: Use a long contact time to ensure proper cervix vessel coagulation, preventing leakage during perfusion.

3. Preparation for perfusion

  1. On a side table, dilate both uterine arteries using a microsurgical dilator and insert an angiocatheter. Secure the cannulation with 3-0 silk ties (Figure 2B).
    NOTE: Here, an 18 G angiocatheter was used for all arteries. Care must be taken not to insert the catheter too far to avoid selective cannulation, as the bifurcation is relatively close. The uterine veins are not cannulated, as venous outflow is sufficient to keep the lumen of these vessels open, allowing easy collection. In addition to saving time, traumatic cannulation may lead to vascular damage and potentially affect venous flow.
  2. Slowly manually flush both uterine arteries with 20 mL of heparin solution on each side until all the vessels are washed out and the outflows are clear.
    NOTE: Attention must be paid not to flush with high pressure, which can lead to microvascular injuries and perfusion failure.
  3. Weigh the uterus.

4. Subnormothermic machine perfusion

NOTE: For the uterus, two independent systems of machine perfusion are required. Each uterine artery is connected to a perfusion system composed of a roller pump, an oxygenator, a bubble trap, and a pressure sensor. The perfusate in a reservoir circulates through silicone tubes connected to the elements listed above before running through the organ via the uterine artery to the uterine vein on each side, where the perfusate exits and is released in the same reservoir.

  1. Connect the uterus to the machine perfusion systems by connecting the uterine artery cannulas into the inflow tubing (Figure 1).
  2. Using the roller pump, adjust the flow rate to low (2.5-4.0 mL/min) to maintain a constant arterial pressure between 25-35 mmHg.
  3. Assess viability parameters at each predefined time point in both inflow and outflow using a 1 mL syringe and analyzing samples with the blood gas system machine [e.g., blood gas metrics (pH, pCO2, pO2, lactate, base excess, bicarbonate), glucose, sodium, potassium, calcium, chloride].
    NOTE: In this protocol, the perfusion lasts for 4 h, and samples from the inflow and the outflow are taken every 30 min.
  4. Weigh the uterus at the end of perfusion.

Results

During perfusion, the system was connected to a pressure sensor that recorded the pressure during the experiment. The pressure was initially recorded for a uterus-free system, which was subtracted from pressure recordings during uterus perfusion to obtain the real organ pressure. The flow rate was adapted to maintain the pressure within the desired range and was controlled by the roller pump. The resistance was calculated using the formula R = P / Q (R: resistance (mmHg.mL.min-1); P: pressure (mmHg); Q: flow r...

Discussion

Uterus transplantation, often considered part of VCA, has rapidly developed in the last few years. In parallel, machine perfusion started to be explored in VCA since it demonstrated robust evidence in improving solid organ preservation. Hypothermic and subnormothermic machine perfusion has allowed up to 24 h preservation in swine models of myocutaneous and bone-containing VCA26,27,28. Since the uterus presents challenges compara...

Disclosures

All authors have no financial interest to declare.

Acknowledgements

This work was partially funded by the National Institute of Health under award No R01AR082825 (BEU) and Shriners Children's 84308 (YB). HO and YB received funding from the Fondation des Gueules Cassées. Support from Société Française de Chirurgie Plastique, Reconstructrice et Esthétique (SOFCPRE, France), and CHU de Rennes (France) to YB is greatly acknowledged.

Materials

NameCompanyCatalog NumberComments
Affinity Pixie Oxygenation SystemMedtronicBBP241Oxygenator
Bovin serum albuminSigma-AldrichA9647Perfusate component
Calcium chloride dihydrateSigma-Aldrich223506Perfusate component
Carbon Dioxide OxygenAirgasUN3156Carbon Dioxide Oxygen mix gas 
D-(+)-Glucose monohydrateSigma-Aldrich49159Perfusate component
DexamethasoneSigma-AldrichD2915Perfusate component
DextranThermo scientific406271000Perfusate component
Heparin sodium injectionEugia Pharma63739-953-25Perfusate component
Humulin Regular Insulin humanLilly0002-8215-01Perfusate component
Hydrocortisone sodium succinatePfizer0009-0011-03Perfusate component
Magnesium chloride hexa-hydrateSigma-AldrichM9272Perfusate component
MasterFlex L/SCole-Parmer77200-32Roller pump
Polyethylene glycol 35000Sigma-Aldrich25322-68-3Perfusate component
Potassium chlorideSigma-Aldrich7447-40-7Perfusate component
Pressure Monitor, Portable, PM-P-1Living Systems InstrumentationPM-P-1Pressure sensor
Radnoti Bubble Trap Compliance ChamberRadnoti130149Bubble trap
RAPIDPoint500Siemens500Blood Gas System
Sodium bicarbonateSigma-AldrichS5761Perfusate component
Sodium chlorideSigma-AldrichS9888Perfusate component
Sodium hydroxideSigma-Aldrich72068Perfusate component
Sodium phosphate monobasique dihydrate Sigma-Aldrich71505Perfusate component
Syringe 1 mLBD309659Sample procurement
Vancomycine hydrochlorideSlate run pharmaceuticals70436-021-82Perfusate component

References

  1. Ejzenberg, D., et al. Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility. Lancet. 392 (10165), 2697-2704 (2019).
  2. Fageeh, W., Raffa, H., Jabbad, H., Marzouki, A. Transplantation of the human uterus. Int J Gynaecol Obstet. 76 (3), 245-251 (2002).
  3. Lavoue, V., et al. Which donor for uterus transplants: brain-dead donor or living donor? A systematic review. Transplantation. 101 (2), 267-277 (2017).
  4. Brännström, M., et al. Registry of the International Society of Uterus Transplantation: First report. Transplantation. 107 (1), 172-181 (2023).
  5. Van Dieren, V., et al. Acute rejection rates in vascularized composite allografts: A systematic review of case reports. J Surg Res. 298, 33-44 (2024).
  6. Kristek, J., et al. Human uterine vasculature with respect to uterus transplantation: A comprehensive review. J Obs Gynaecol Res. 46 (11), 1999-2007 (2020).
  7. He, J., Khan, U. Z., Qing, L., Wu, P., Tang, J. Improving the ischemia-reperfusion injury in vascularized composite allotransplantation: Clinical experience and experimental implications. Front Immunol. 13, 998952 (2022).
  8. Ponticelli, C. Ischaemia-reperfusion injury: A major protagonist in kidney transplantation. Nephrol Dial Transplant. 29 (6), 1134-1140 (2014).
  9. Harris, K., et al. Metabolic response of skeletal muscle to ischemia. Am J Physiol. 250 (2 Pt 2), H213-H220 (1986).
  10. Wranning Almen, C., et al. Short-term ischaemic storage of human uterine myometrium--basic studies towards uterine transplantation. Hum Reprod. 20 (10), 2736-2743 (2005).
  11. Bodewes, S. B., et al. Oxygen transport during ex situ machine perfusion of donor livers using red blood cells or artificial oxygen carriers. Int J Mol Sci. 22 (1), 235 (2020).
  12. Boncompagni, E., et al. Decreased apoptosis in fatty livers submitted to subnormothermic machine-perfusion respect to cold storage. Eur J Histochem. 55 (4), e40 (2011).
  13. Czigany, Z., et al. Hypothermic oxygenated machine perfusion reduces early allograft injury and improves post-transplant outcomes in extended criteria donation liver transplantation from donation after brain death: Results from a Multicenter Randomized Controlled Trial (HOPE ECD-DBD). Ann Surg. 274 (5), 705-712 (2021).
  14. Markmann, J. F., et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: The OCS Liver PROTECT randomized clinical trial. JAMA Surg. 157 (3), 189-198 (2022).
  15. Cypel, M., et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. New Eng J Med. 364 (15), 1431-1440 (2011).
  16. Roesel, M. J., Ius, F., Knosalla, C., Iske, J. The role of ex-situ perfusion for thoracic organs. Curr Opin Organ Transplant. 27 (5), 466-473 (2022).
  17. Michel, S. G., et al. Twelve-hour hypothermic machine perfusion for donor heart preservation leads to improved ultrastructural characteristics compared to conventional cold storage. Ann Transplant. 20, 461-468 (2015).
  18. Ghoneima, A. S., Sousa Da Silva, R. X., Gosteli, M. A., Barlow, A. D., Kron, P. Outcomes of kidney perfusion techniques in transplantation from deceased donors: A systematic review and meta-analysis. J Clin Med. 12 (12), 3221 (2023).
  19. Charlès, L., et al. Effect of subnormothermic machine perfusion on the preservation of vascularized composite allografts after prolonged warm ischemia. Transplantation. 108 (5), e280-e290 (2024).
  20. Duru, &. #. 1. 9. 9. ;., et al. Review of machine perfusion studies in vascularized composite allotransplant preservation. Front Transplantation. 2, 103-111 (2023).
  21. Brännström, M., Diaz-Garcia, C., Hanafy, A., Olausson, M., Tzakis, A. Uterus transplantation: Animal research and human possibilities. Fertil Steril. 97 (6), 1269-1276 (2012).
  22. Wranning, C. A., et al. Auto-transplantation of the uterus in the domestic pig (Sus scrofa): Surgical technique and early reperfusion events. J Obstet Gynaecol Res. 32 (4), 358-367 (2006).
  23. Croome, K. P., et al. American Society of Transplant Surgeons recommendations on best practices in donation after circulatory death organ procurement. Am J Transplant. 23 (2), 171-179 (2023).
  24. Dickens, B. M. Legal and ethical issues of uterus transplantation. Int J Gynaecol Obstet. 133 (1), 125-128 (2016).
  25. Díaz, L., et al. Ethical considerations in animal research: The Principle of 3R's. Rev Invest Clin. 73 (4), 199-209 (2020).
  26. Goutard, M., et al. Machine perfusion enables 24-h preservation of vascularized composite allografts in a swine model of allotransplantation. Transpl Int. 37 (1), 102-111 (2024).
  27. Berkane, Y., et al. Towards optimizing sub-normothermic machine perfusion in fasciocutaneous flaps: A large animal study. Bioengineering (Basel). 10 (12), 1545 (2023).
  28. Brouwers, K., et al. 24-hour perfusion of porcine myocutaneous flaps mitigates reperfusion injury: a 7-day follow-up study. Plast Reconstr Surg Glob Open. 10 (2), e4123 (2022).
  29. Richter, O., et al. Extracorporeal perfusion of the human uterus as an experimental model in gynaecology and reproductive medicine. Human Reprod. 15 (6), 1235-1240 (2000).
  30. O'Neill, K., et al. Availability of deceased donors for uterus transplantation in the United States: Perception vs Reality. Transplantology. 5 (1), 27-36 (2024).
  31. Chan, J. K., Morrow, J., Manetta, A. Prevention of ureteral injuries in gynecologic surgery. Am J Obstet Gynecol. 188 (5), 1273-1277 (2003).
  32. Rocca, W. A., et al. Accelerated accumulation of multimorbidity after bilateral oophorectomy: A population-based cohort study. Mayo Clin Proc. 91 (11), 1577-1589 (2016).
  33. Dion, L., et al. Procurement of uterus in a deceased donor multi-organ donation National Program in France: A scarce resource for uterus transplantation. J Clin Med. 11 (3), 730 (2022).
  34. Agarwal, A., et al. Clinicopathological analysis of uterine allografts including proposed scoring of ischemia reperfusion injury and t-cell-mediated rejection-dallas uterus transplant study: A pilot study. Transplantation. 106 (1), e10-e20 (2022).
  35. Díaz-García, L., et al. Pregnancy in transplanted mouse uterus after long-term cold ischaemic preservation. Hum Reprod. 18 (10), 2142-2150 (2003).
  36. Tricard, J., et al. Uterus tolerance to extended cold ischemic storage after auto-transplantation in ewes. Eur J Obstet Gynecol Reprod Biol. 214, 162-167 (2017).
  37. Dion, L., et al. Hypothermic machine perfusion for uterus transplantation. Fertil Steril. 120 (6), 1259-1261 (2023).
  38. Brännström, M., et al. Experimental uterus transplantation. Hum Reprod Update. 16 (3), 329-340 (2010).
  39. Ozkan, O., Ozkan, O., Dogan, N. U. The Ozkan technique in current use in uterus transplantation: from the first ever successful attempt to clinical reality. J Clin Med. 12 (8), 2812 (2023).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Uterus TransplantationAbsolute Uterine InfertilityRokitansky SyndromeIschemia reperfusion InjuryGraft QualityGraft RejectionThrombotic ComplicationsEndothelial Cell DamageHypoxiaStatic Cold StorageDynamic PreservationMachine PerfusionPorcine Uterus ProcurementSurgical Protocol

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved